Everyone wants an ADC: GSK pays $85M upfront for ex-China rights to Hansoh Pharma's antibody-drug conjugate

Lei Lei Wu

News Reporter

MADRID — GSK has agreed to license an antibody-drug conjugate from Hansoh Pharma for $85 million upfront, in exchange for global rights outside of China, Hong …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Everyone wants an ADC: GSK pays $85M upfront for ex-China rights to Hansoh Pharma's antibody-drug conjugate

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Every­one wants an ADC: GSK pays $85M up­front for ex-Chi­na rights to Han­soh Phar­ma's an­ti­body-drug con­ju­gate

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Everyone wants an ADC: GSK pays $85M upfront for ex-China rights to Hansoh Pharma's antibody-drug conjugate